Clinical Trials Browser

Leukemia × quizartinib × Clear all

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Phase 1 Recruiting

Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT06578247 2026-02-27

QuANTUM-WILD

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

Phase 3 Completed

539 enrolled 20 charts 1 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02039726 2021-02-24

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Phase 3 Completed

367 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Phase 1 Completed

76 enrolled 12 charts

MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT00989261 2019-12-11

ACE

Phase 2 Completed

333 enrolled 23 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute